Kalaris Therapeutics Inc (KLRS)

$5.89 -0.03 (-0.59%)
Market Cap 110.06M
Revenue (ttm) 0.00
Net Income (ttm) -58.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 34,200
Avg Vol 169,704
Day's Range N/A - N/A
Shares Out 18.70M
Stochastic %K 40%
Beta -0.04
Analysts Strong Sell
Price Target $17.80

Company Profile

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

Industry: Biotechnology
Sector: Healthcare
Address:
628 Middlefield Road, Palo Alto, United States
Orlandotrader
Orlandotrader Dec. 5 at 4:35 PM
$KLRS Liking this Quit and Unnoticed Equity and Board. Lots of Upside for this 18 Million 114 Million MCP Gem.
0 · Reply
Orlandotrader
Orlandotrader Dec. 4 at 8:52 PM
$KLRS Slow and Steady!!! Phase 1/2 Data to come before Years end to Notify of Dosage to deploy for Phase 2 Trial. CEO is Renowned Scientist in the field of Anti VEGG. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF
0 · Reply
newsfile_corp
newsfile_corp Nov. 24 at 1:02 PM
https://nfne.ws/275547 $KLRS #Banking #FinancialServices #NASDAQ #Investing
0 · Reply
WallStArb
WallStArb Nov. 21 at 6:40 PM
$KLRS i sold about 1/2 last few days $7 area. I am moving some into $IMA for a similar play but its a 9mo time horizon - trades at a nice 40% discount to NET CASH (about $12 a share as of today) - good upside for a big market (Dupixent & IL-4 / IL-13 Biologic is SOC for older - IMG-007 is non-depleting anti-OX40 mAb - less frequent dosing and better tolerability). Good upside and no real need to dilute for cash - downside is that Phase 2B data not expect until Q4 2026. Potential partner catalyst and they submitted protocol amendment for IMG‑007 Phase 2B
0 · Reply
WallStArb
WallStArb Nov. 19 at 5:40 PM
$KLRS moving some $ as I can from $KLRS to other similar ideas - yheees not too much left that are cheap with catalyst
0 · Reply
WallStArb
WallStArb Nov. 19 at 5:34 PM
$KLRS starting to exit some of our position in the $7 area today - will derisk as opportunity presents expect to exit 1/3 to recoup our cost from $2.40 average
0 · Reply
TV010
TV010 Nov. 19 at 3:29 PM
$KLRS lookin up
0 · Reply
Orlandotrader
Orlandotrader Nov. 15 at 4:56 PM
$KLRS Creaping Higher into December Data Release. Optimal Dosing and Efficacy Results for Phase 2 Trial.
0 · Reply
d_risk
d_risk Nov. 12 at 10:16 PM
$KLRS - Kalaris Therapeutics, Inc. - 10Q - Updated Risk Factors KLRS’s 10-Q risk factors for 2025 expand on clinical, financial, and regulatory uncertainties, highlight new dilution and capital-raising risks, detail ongoing internal control weaknesses, add threats from tariffs and healthcare reforms, and disclose concentrated insider control—while streamlining redundancies and removing outdated risks. #Biotechnology #CapitalRaising #RegulatoryCompliance #FinancialUncertainty #ClinicalRisks 🟢 Added 🟠 Removed https://d-risk.ai/KLRS/10-Q/2025-11-12
0 · Reply
WallStArb
WallStArb Nov. 12 at 3:02 PM
$KLRS exiting some on their 10Q updates
0 · Reply
Latest News on KLRS
Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Nov 24, 2025, 8:00 AM EST - 13 days ago

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 12, 2025, 8:00 AM EST - 25 days ago

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Nov 3, 2025, 7:30 AM EST - 4 weeks ago

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Oct 30, 2025, 8:00 AM EDT - 5 weeks ago

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Sep 15, 2025, 3:26 PM EDT - 2 months ago

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Sep 15, 2025, 8:00 AM EDT - 2 months ago

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 13, 2025, 8:00 AM EDT - 4 months ago

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Jun 2, 2025, 8:00 AM EDT - 6 months ago

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

Kalaris to Participate at Stifel Ophthalmology Forum

May 23, 2025, 11:03 AM EDT - 7 months ago

Kalaris to Participate at Stifel Ophthalmology Forum

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025, 8:00 AM EDT - 7 months ago

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Apr 4, 2025, 8:00 AM EDT - 8 months ago

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Kalaris Announces Closing of Merger with AlloVir

Mar 18, 2025, 4:21 PM EDT - 9 months ago

Kalaris Announces Closing of Merger with AlloVir

ALVR

Orlandotrader
Orlandotrader Dec. 5 at 4:35 PM
$KLRS Liking this Quit and Unnoticed Equity and Board. Lots of Upside for this 18 Million 114 Million MCP Gem.
0 · Reply
Orlandotrader
Orlandotrader Dec. 4 at 8:52 PM
$KLRS Slow and Steady!!! Phase 1/2 Data to come before Years end to Notify of Dosage to deploy for Phase 2 Trial. CEO is Renowned Scientist in the field of Anti VEGG. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF
0 · Reply
newsfile_corp
newsfile_corp Nov. 24 at 1:02 PM
https://nfne.ws/275547 $KLRS #Banking #FinancialServices #NASDAQ #Investing
0 · Reply
WallStArb
WallStArb Nov. 21 at 6:40 PM
$KLRS i sold about 1/2 last few days $7 area. I am moving some into $IMA for a similar play but its a 9mo time horizon - trades at a nice 40% discount to NET CASH (about $12 a share as of today) - good upside for a big market (Dupixent & IL-4 / IL-13 Biologic is SOC for older - IMG-007 is non-depleting anti-OX40 mAb - less frequent dosing and better tolerability). Good upside and no real need to dilute for cash - downside is that Phase 2B data not expect until Q4 2026. Potential partner catalyst and they submitted protocol amendment for IMG‑007 Phase 2B
0 · Reply
WallStArb
WallStArb Nov. 19 at 5:40 PM
$KLRS moving some $ as I can from $KLRS to other similar ideas - yheees not too much left that are cheap with catalyst
0 · Reply
WallStArb
WallStArb Nov. 19 at 5:34 PM
$KLRS starting to exit some of our position in the $7 area today - will derisk as opportunity presents expect to exit 1/3 to recoup our cost from $2.40 average
0 · Reply
TV010
TV010 Nov. 19 at 3:29 PM
$KLRS lookin up
0 · Reply
Orlandotrader
Orlandotrader Nov. 15 at 4:56 PM
$KLRS Creaping Higher into December Data Release. Optimal Dosing and Efficacy Results for Phase 2 Trial.
0 · Reply
d_risk
d_risk Nov. 12 at 10:16 PM
$KLRS - Kalaris Therapeutics, Inc. - 10Q - Updated Risk Factors KLRS’s 10-Q risk factors for 2025 expand on clinical, financial, and regulatory uncertainties, highlight new dilution and capital-raising risks, detail ongoing internal control weaknesses, add threats from tariffs and healthcare reforms, and disclose concentrated insider control—while streamlining redundancies and removing outdated risks. #Biotechnology #CapitalRaising #RegulatoryCompliance #FinancialUncertainty #ClinicalRisks 🟢 Added 🟠 Removed https://d-risk.ai/KLRS/10-Q/2025-11-12
0 · Reply
WallStArb
WallStArb Nov. 12 at 3:02 PM
$KLRS exiting some on their 10Q updates
0 · Reply
TV010
TV010 Nov. 12 at 1:11 PM
$KLRS https://investors.kalaristx.com/news-releases/news-release-details/kalaris-reports-third-quarter-2025-financial-results-and
0 · Reply
TV010
TV010 Nov. 11 at 5:35 PM
$KLRS Looking up
0 · Reply
WallStArb
WallStArb Nov. 6 at 6:01 PM
$KLRS look from a fast sell off and break down to low $3 area - rebuy if its prior to data
0 · Reply
NicoleToki632
NicoleToki632 Nov. 4 at 4:35 PM
$KLRS shows potential in adopting smart infrastructure and automation systems as AITX adds a major U.S. healthcare system client, moving from pilot to paid deployments as hospitals adopt RIO 360 units to enhance safety and efficiency.
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 2:05 PM
Citizens has adjusted their stance on Kalaris Therapeutics ( $KLRS ), setting the rating to Market Outperform with a target price of 20.
0 · Reply
WallStArb
WallStArb Oct. 29 at 5:21 PM
$KLRS low bar for data in the next 8 weeks - should be easy to put up decent 1B results
1 · Reply
RosaMueller940
RosaMueller940 Oct. 21 at 4:46 PM
$KLRS developing clinical breakthroughs, AITX developing commercial breakthroughs — a profitable quarter confirms strategic strength.
0 · Reply
Beardedd
Beardedd Oct. 13 at 11:23 PM
$KLRS is good data coming here or what? Took a position at 4.48
2 · Reply
Goldenryu
Goldenryu Oct. 10 at 9:01 AM
$KLRS any news to justify the drop?
0 · Reply
Orlandotrader
Orlandotrader Oct. 9 at 9:03 PM
$KLRS Be patient and Load . Started at 5.50 and will add tomorrow. Eventually will have to hold some for Clinical Data in Fourth Quarter.
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 9 at 7:52 PM
$KLRS -9%[-32%] $NUAI 9%[76%] $BJDX -5%[79%] $BDRX 4%[41%] $BAOS -4%[45%] most notable movement into the final minutes of trading.
0 · Reply
Orlandotrader
Orlandotrader Oct. 9 at 5:45 PM
$KLRS Time to Reload!!!
1 · Reply